Cationic core-shell nanoparticles with carmustine contained within O6-benzylguanine shell for glioma therapy

Biomaterials

Volumn 34, Issue 35, 2013, Pages 8968-8978

  Qian, Lili ^a   Zheng, Jiajun ^b   Wang, Ke ^a   Tang, Ying ^b   Zhang, Xiaofeng ^a   Zhang, Haishi ^b   Huang, Fengping ^b   Pei, Yuanying ^a   Jiang, Yanyan ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Carmustine; Chitosan; Glioma; Nanoparticles; O6 benzylguanine; Poly (lactide co glycolides)

Indexed keywords

CARMUSTINE; CIRCULATION TIME; CORE SHELL STRUCTURE; CORE-SHELL NANOPARTICLES; GLIOBLASTOMA CELLS; GLIOMA; POLY (LACTIDE-CO-GLYCOLIDES); SURFACE-MODIFIED;

CHITOSAN; NANOPARTICLES; PLASMA STABILITY;

TUMORS;

6 O BENZYLGUANINE; CARMUSTINE; CHITOSAN; NANOPARTICLE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG STABILITY; GLIOMA; HUMAN; HUMAN CELL; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; TUMOR VOLUME; ZETA POTENTIAL;

RATTUS;

CARMUSTINE; CHITOSAN; GLIOMA; NANOPARTICLES; O(6)-BENZYLGUANINE; POLY (LACTIDE-CO-GLYCOLIDES);

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CATIONS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GLIOBLASTOMA; GUANINE; MAGNETIC RESONANCE IMAGING; MALE; NANOPARTICLES; PHYSICOCHEMICAL PHENOMENA; RATS; RATS, INBRED F344;

EID: 84883250012     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.097     Document Type: Article

References (40)

1. Merrell R.T. Brain tumors. Dm-Dis Mon 2012, 58(12):678-689.
2. Allhenn D., Boushehri M.A., Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm 2012, 436:299-310.
3. Anton K., Baehring J.M., Mayer T. Glioblastoma multiforme overview of current treatment and future perspectives. Hematol Oncol Clin North Am 2012, 26(4):825.
4. Silvani A., Gaviani P., Lamperti E., Botturi A., Ferrari D., Simonetti G., et al. Malignant gliomas: early diagnosis and clinical aspects. Neurol Sci 2011, 32.
5. Xu X., Chen X., Xu X., Lu T., Wang X., Yang L., et al. BCNU-loaded PEG-PLLA ultrafine fibers and their invitro antitumor activity against glioma C6 cells. JControl Release 2006, 114(3):307-316.
6. Seong H., An T.K., Khang G., Choi S.U., Lee C.O., Lee H.B. BCNU-loadedpoly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells invitro. Int J Pharm 2003, 251:1-12.
7. Li Y.W., Duc H., Tyler B., Williams T., Tupper M., Langer R., et al. Invivo delivery of BCNU from a MEMS device to a tumor model. JControl Release 2005, 106(1-2):138-145.
8. Lee J.S., An T.K., Chae G.S., Jeong J.K., Cho S.H., Lee H.B., et al. Evaluation of invitro and invivo antitumor activity of BCNU-Ioaded PLGA wafer against 9L gliosarcoma. Eur J Pharm Biopharm 2005, 59(1):169-175.
9. Han L., Ren Y., Long L., Zhong Y., Shen C., Pu P., et al. Inhibition of C6 glioma invivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles. Oncol Rep 2012, 27(1):121-128.
10. McGovern P.C., Lautenbach E., Brennan P.J., Lustig R.A., Fishman N.O. Risk factors for postcraniotomy surgical site infection after 1,3-bis(2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 2003, 36(6):759-765.
11. 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemoth Pharm 2006, 58(5):634-639.
12. 6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 2005, 11(7):2747-2755.
13. 6-alkylguanine-DNA alkytransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. JPharmacol Exp Ther 2005, 315(3):1247-1255.
14. 6-benzyl-2 '-deoxyguanosine. Clin Cancer Res 2003, 9(10):3801-3807.
15. 6-Benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 2000, 60(22):6307-6310.
16. 6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemoth Pharm 2007, 60(3):415-421.
17. 6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. Arch Dermatol 2012, 148(5):613-620.
18. Paoletti P. Therapeutic strategy for central nervous system tumors: present status, criticism and potential. JNeurosurg Sci 1984, 28(2):51-60.
19. 6-benzylguanine in adults with recurrent malignant glioma: New approaches to brain tumor therapy CNS consortium trial. JClin Oncol 2007, 25(4):399-404.
20. Agarwal A., Lariya N., Saraogi G., Dubey N., Agrawal H., Agrawal G.P. Nanoparticles as novel carrier for brain delivery: a review. Curr Pharm Des 2009, 15(8):917-925.
21. Roney C., Kulkarni P., Arora V., Antich P., Bonte F., Wu A., et al. Targeted nano-particles for drug delivery through the blood-brain barrier for Alzheimer's disease. JControl Release 2005, 108(2-3):193-214.
22. Yung C.C., Wen Y.H., Wen F.L., Ding T.Z. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier. JBiomater Appl 2013, 27:909.
23. Akbar U., Jones T., Winestone J., Michael M., Shukla A., Sun Y., et al. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. JNeuro-Oncol 2009, 94(2):203-212.
24. Wang Z.H., Wang Z.Y., Sun C.S., Wang C.Y., Jiang T.Y., Wang S.L. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010, 31(5):908-915.
25. Yang R., Shim W., Cui F., Cheng G., Han X., Jin Q., et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm 2009, 371(1-2):142-147.
26. Zeng P., Xu Y., Zeng C., Ren H., Peng M. Chitosan-modified poly(D, L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Int J Pharm 2011, 415(1-2):259-266.
27. Nafee N., Taetz S., Schneider M., Schaefer U.F., Lehr C. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomed-Nanotechnol 2007, 3(3):173-183.
28. 6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000, 6(8):3025-3031.
29. Yang M.B., Tamargo R.J., Brem H. Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 1989 sep 15, 49(18):5103-5107.
30. Chae G.S., Lee J.S., Kim S.H., Seo K.S., Kim M.S., Lee H.B., et al. Enhancement of the stability of BCNU using self-emulsifying drug deliver systems (SEDDS) and invitro antitumor activity of self-emulsified BCNU-loaded PLGA water. Int J Pharm 2005, 301(1-2):6-14.
31. Chung T., Wang S., Tsai W. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles. Biomaterials 2008, 29(2):228-237.
32. Tahara K., Sakai T., Yamamoto H., Takeuchi H., Hirashima N., Kawashima Y. Improved cellular uptake of chitosan-modifled PLGA nanospheres by A549 cells. Int J Pharm 2009, 382(1-2):198-204.
33. Zhang N., Chittasupho C., Duangrat C., Siahaan T.J., Berkland C. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjugate Chem 2008, 19(1):145-152.
34. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9(8):615-627.
35. 6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1, 3-bis (2-chloroethyl)-1-nitrosourea sensitivity invitro. Cancer Res 1993, 53(18):4281-4286.
36. Wedge S.R., Porteous J.K., Newlands E.S. 3-Aminobenzamide and/or 06-benzylguanin eevaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and 06-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996, 74:1030-1036.
37. Yang H., Hua M., Liu H., Huang C., Tsai R., Lu Y. Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials 2011, 32(27):6523-6532.
38. Li S., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5(4):496-504.
39. Banerjee T., Mitra S., Singh A.K., Sharma R.K., Maitra A. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 2002, 243:93-105.
40. Chung Y., Kim J.C., Kim Y.H., Tae G., Lee S., Kim K., et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated pluronic on tumor targeting. JControl Release 2010, 143(3):374-382.